[go: up one dir, main page]

MX2019005144A - Tratamiento de cáncer de mama positivo para her2. - Google Patents

Tratamiento de cáncer de mama positivo para her2.

Info

Publication number
MX2019005144A
MX2019005144A MX2019005144A MX2019005144A MX2019005144A MX 2019005144 A MX2019005144 A MX 2019005144A MX 2019005144 A MX2019005144 A MX 2019005144A MX 2019005144 A MX2019005144 A MX 2019005144A MX 2019005144 A MX2019005144 A MX 2019005144A
Authority
MX
Mexico
Prior art keywords
her2
trastuzumab
breast cancer
treatment
administration
Prior art date
Application number
MX2019005144A
Other languages
English (en)
Inventor
Douthwaite Hannah
Waldron-Lynch Maeve
BRADLEY Denise
ENG-WONG Jennifer
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2019005144A publication Critical patent/MX2019005144A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proveen métodos para el tratamiento de cáncer de mama positivo para HER2 mediante administración neoadyuvante de pertuzumab y trastuzumab en combinación con quimioterapia a base de antraciclina. En particular, los métodos conciernen los pacientes de tratamiento con cáncer de mama positivo para HER2 de estadio temprano, inflamatorio o localmente avanzado mediante administración de neoadyuvantes de pertuzumab y trastuzumab después de quimioterapia a base de antraciclina, en donde la administración combinada de pertuzumab y trastuzumab aumenta la respuesta completa patológica (pCR) con respecto a la administración de trastuzumab como agente simple, sin aumento significativo de eventos adversos, tales como toxicidad cardíaca, con referencia a quimioterapia con base en antraciclina neoadyuvante.
MX2019005144A 2016-11-04 2017-11-02 Tratamiento de cáncer de mama positivo para her2. MX2019005144A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662417966P 2016-11-04 2016-11-04
PCT/US2017/059680 WO2018085513A1 (en) 2016-11-04 2017-11-02 Treatment of her2-positive breast cancer

Publications (1)

Publication Number Publication Date
MX2019005144A true MX2019005144A (es) 2019-10-14

Family

ID=61257088

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005144A MX2019005144A (es) 2016-11-04 2017-11-02 Tratamiento de cáncer de mama positivo para her2.

Country Status (11)

Country Link
US (1) US20180134803A1 (es)
EP (1) EP3534948A1 (es)
JP (1) JP2019532999A (es)
KR (1) KR20190075114A (es)
CN (1) CN110505880A (es)
AU (1) AU2017355432A1 (es)
CA (1) CA3040913A1 (es)
IL (1) IL266324A (es)
MX (1) MX2019005144A (es)
TW (1) TW201818940A (es)
WO (1) WO2018085513A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
CN104334189A (zh) 2011-10-14 2015-02-04 霍夫曼-拉罗奇有限公司 Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品
CA2907776C (en) 2013-04-16 2020-04-14 Genentech, Inc. Pertuzumab variants and evaluation thereof
US10380152B2 (en) * 2016-01-19 2019-08-13 International Business Machines Corporation Cognitive system comparison and recommendation engine
EP3868404A1 (en) 2017-01-17 2021-08-25 F. Hoffmann-La Roche AG Subcutaneous her2 antibody formulations
US11077189B2 (en) * 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
MX2022008632A (es) * 2020-01-13 2022-08-08 Cytodyn Inc Agente de union a ccr5 para el tratamiento de cancer metastasico positivo para ccr5.
WO2022005499A1 (en) 2020-06-29 2022-01-06 Genentech, Inc. Pertuzumab plus trastuzumab fixed dose combination
WO2024242443A1 (en) * 2023-05-24 2024-11-28 Lunit Inc. Method and device for predicting treatment response to her2-targeted therapeutic agent

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
DE69031120T2 (de) 1989-05-19 1998-01-15 Genentech, Inc., South San Francisco, Calif. Her2 extrazellulare domäne
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
ATE371673T1 (de) 1996-11-27 2007-09-15 Genentech Inc Affinitätsreinigung von polypeptiden an einer protein a-matrix
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
CA2324494A1 (en) 1998-03-27 1999-09-30 Genentech, Inc. Apo-2 ligand-anti-her-2 antibody synergism
SI1308455T1 (sl) 1998-05-06 2006-08-31 Genentech Inc Sestavek, ki obsega protitelesa anti-HER2
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
SI1187632T1 (sl) 1999-05-14 2009-04-30 Genentech Inc Zdravljenje z anti-ErbB2 protitelesi
PT1189634E (pt) 1999-06-25 2007-06-06 Genentech Inc Tratamento de cancro da próstata com anticorpos anti-erbb2.
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
TR200200472T2 (tr) 1999-08-27 2002-06-21 Genentech, Inc. Anti-Erb B2 antikorları ile tedavi için dozajlar
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
SI1282443T1 (sl) 2000-05-19 2010-01-29 Genentech Inc Metoda detekcije gena za izboljšanje verjetnosti učinkovitega odziva na terapijo raka z antagonistom ErbB
US6984494B2 (en) 2000-08-15 2006-01-10 Genentech, Inc. Analytical method
US6695940B2 (en) 2001-04-05 2004-02-24 Alan D. Devoe Laminate thin-wall ceramic tubes, including with integral stress wrappings, thickened ends and/or internal baffles, particularly for solid oxide fuel cells
US20040048525A1 (en) 2002-01-28 2004-03-11 Sagucio Esteban N. Watercycle for wet rider
WO2003087131A2 (en) 2002-04-10 2003-10-23 Genentech, Inc Anti-her2 antibody variants
JP5069843B2 (ja) 2002-07-15 2012-11-07 ジェネンテック， インコーポレイテッド 抗ＥｒｂＢ２抗体を用いる処置に応答性である腫瘍を同定するための方法
US6982719B2 (en) 2002-07-15 2006-01-03 Sun Microsystems, Inc. Switching sample buffer context in response to sample requests for real-time sample filtering and video generation
WO2004048525A2 (en) 2002-11-21 2004-06-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
LT3095793T (lt) 2003-07-28 2020-07-10 Genentech, Inc. Baltymo a išplovimo sumažinimas afininės baltymo a chromatografijos metu
AU2005232657B2 (en) 2004-04-08 2010-12-16 David B. Agus ErbB antagonists for pain therapy
US7195440B2 (en) 2004-05-27 2007-03-27 Lambert Charles F Agricultural silo auger system apparatus and method
EP1753463A2 (en) 2004-06-01 2007-02-21 Genentech, Inc. Antibody drug conjugates and methods
SV2006002143A (es) 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
KR20150043558A (ko) 2004-07-22 2015-04-22 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006063042A2 (en) 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
RU2438705C2 (ru) 2005-01-21 2012-01-10 Дженентек, Инк. Введение фиксированных доз her-антител
CA2596133C (en) 2005-02-23 2016-11-15 Genentech, Inc. Extending time to disease progression or survival in cancer patients
WO2006096861A2 (en) 2005-03-08 2006-09-14 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
US20090148401A1 (en) 2005-12-05 2009-06-11 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
WO2008031531A1 (en) 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
BRPI0812682A2 (pt) * 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
WO2011147982A2 (en) * 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2 epitope
KR20140009275A (ko) * 2010-12-09 2014-01-22 제넨테크, 인크. 파클리탁셀 및 트라스투주맙-mcc-dm1에 의한 her2-양성 암의 치료
CN104334189A (zh) * 2011-10-14 2015-02-04 霍夫曼-拉罗奇有限公司 Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品
WO2014205138A1 (en) * 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Estrogen receptor modulator and uses thereof

Also Published As

Publication number Publication date
US20180134803A1 (en) 2018-05-17
JP2019532999A (ja) 2019-11-14
TW201818940A (zh) 2018-06-01
IL266324A (en) 2019-06-30
EP3534948A1 (en) 2019-09-11
AU2017355432A1 (en) 2019-05-16
KR20190075114A (ko) 2019-06-28
WO2018085513A9 (en) 2018-07-19
WO2018085513A1 (en) 2018-05-11
CA3040913A1 (en) 2018-05-11
CN110505880A (zh) 2019-11-26

Similar Documents

Publication Publication Date Title
MX2019005144A (es) Tratamiento de cáncer de mama positivo para her2.
MX2021014137A (es) Pertuzumab para usarse en el tratamiento de cancer de mama her2 positivo.
AU2015249633A8 (en) Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
WO2019094692A3 (en) Extracellular vesicle proteins and their use for cancer diagnosis, predicting response to therapy, and treatment
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
PH12015501744A1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
WO2016172494A3 (en) Combination of immunotherapy with local chemotherapy for the treatment of malignancies
MX2021004881A (es) Combinacion de palbociclib y rad1901 para usarse en el tratamiento de cancer de mama en un sujeto con cancer positivo a receptor de estrogeno.
MX2021013938A (es) Metodos y composiciones para prediccion de eficacia terapeutica de tratamientos contra el cancer y prognosis del cancer.
MX2020005640A (es) Anticuerpos anti-liv1 humanizados para el tratamiento de cancer de mama.
PH12019502025A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
MX2023012451A (es) Composiciones para usarse en el tratamiento de una enfermedad autoinmune y cancer.
MX2017015896A (es) Agente anticancerigeno.
HK1220900A1 (zh) 癌症的治疗
WO2016191675A3 (en) Antibodies against glypican-3 and their uses in cancer diagnosis and treatment
WO2017049038A3 (en) Anti-cd115 antibodies
MX2019000677A (es) Células miméticas de células b.
HK1250626A1 (zh) 借助塞里班土单抗的组合治疗
EP3314250A4 (en) Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
PH12021550376A1 (en) Combination therapy
WO2016196373A3 (en) Methods of treating her2-positive locally advanced or previously untreated metastatic breast cancer
BR112019025164A2 (pt) Esquema de dosagem para tesetaxel e capecitabina
WO2015134603A3 (en) Methods for treating cancer